tiprankstipranks
Trending News
More News >

KalVista subsidiary licenses commercialization rights for sebetralstat in Japan

KalVista (KALV) Pharmaceuticals announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has licensed commercialization rights in Japan to Kaken Pharmaceutical, for sebetralstat, an investigational, oral on-demand treatment for hereditary angioedema, or HAE. KalVista will receive an upfront payment of $11M, with an additional payment of up to $11M upon achievement of a regulatory milestone anticipated in early 2026. Beyond these payments, the Company is also eligible for commercial milestone payments, plus royalties based on the Japan National Health Insurance, or NHI, price, with the royalty rate as a percentage of sales approximately in the mid-twenties.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue